Trial Profile
Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs MTBVAC (Primary) ; BCG
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Biofabri
- 26 Aug 2022 Status changed from active, no longer recruiting to completed.
- 06 May 2021 Planned End Date changed from 1 Dec 2020 to 1 Mar 2022.
- 06 May 2021 Status changed from recruiting to active, no longer recruiting.